粪便免疫化学测试(FIT):基于英国初级保健症状患者三年常规测试的结果差异来源。

IF 2.7 4区 医学 Q2 MEDICAL LABORATORY TECHNOLOGY
British Journal of Biomedical Science Pub Date : 2021-10-01 Epub Date: 2021-03-19 DOI:10.1080/09674845.2021.1896204
T James, B D Nicholson, R Marr, M Paddon, J E East, S Justice, J L Oke, B Shine
{"title":"粪便免疫化学测试(FIT):基于英国初级保健症状患者三年常规测试的结果差异来源。","authors":"T James,&nbsp;B D Nicholson,&nbsp;R Marr,&nbsp;M Paddon,&nbsp;J E East,&nbsp;S Justice,&nbsp;J L Oke,&nbsp;B Shine","doi":"10.1080/09674845.2021.1896204","DOIUrl":null,"url":null,"abstract":"<p><p><b>Introduction</b>: We aimed to determine the analytical capabilities of a commonly used faecal immunochemical test (FIT) to detect faecal haemoglobin (Hb) in symptomatic people attending primary care in the context of the English NICE DG30 guidance.<b>Materials and Methods</b>: Data obtained from independent verification studies and clinical testing of the HM-JACKarc FIT method in routine primary care practice were analysed to derive performance characteristics.<b>Results</b>: Detection capabilities for the FIT method were 0.5 µg/g (limit of blank), 1.3 µg/g (limit of detection) and 3.0 µg/g (limit of quantitation). Of 33 non-homogenized specimens, 31 (93.9%) analysed in triplicate were consistently categorized relative to 10 µg/g, compared to all 33 (100%) homogenized specimens. Imprecision was higher (median 27.8%, (range 20.5% to 48.6%)) in non-homogenized specimens than in homogenized specimens (10.2%, (7.0 to 13.5%)). Considerable variation was observed in sequential clinical specimens from individual patients but no positive or negative trend in specimen degradation was observed over time (p = 0.26).<b>Discussion</b>: The FIT immunoassay evaluated is capable of detecting faecal Hb at concentrations well below the DG30 threshold of 10 µg/g and is suitable for application in this context. The greatest practical challenge to FIT performance is reproducible sampling, the pre-analytical step associated with most variability. Further research should focus on reducing sampling variability, particularly as post-COVID-19 guidance recommends greater FIT utilization.</p>","PeriodicalId":9236,"journal":{"name":"British Journal of Biomedical Science","volume":null,"pages":null},"PeriodicalIF":2.7000,"publicationDate":"2021-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1080/09674845.2021.1896204","citationCount":"5","resultStr":"{\"title\":\"Faecal immunochemical testing (FIT): sources of result variation based on three years of routine testing of symptomatic patients in English primary care.\",\"authors\":\"T James,&nbsp;B D Nicholson,&nbsp;R Marr,&nbsp;M Paddon,&nbsp;J E East,&nbsp;S Justice,&nbsp;J L Oke,&nbsp;B Shine\",\"doi\":\"10.1080/09674845.2021.1896204\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Introduction</b>: We aimed to determine the analytical capabilities of a commonly used faecal immunochemical test (FIT) to detect faecal haemoglobin (Hb) in symptomatic people attending primary care in the context of the English NICE DG30 guidance.<b>Materials and Methods</b>: Data obtained from independent verification studies and clinical testing of the HM-JACKarc FIT method in routine primary care practice were analysed to derive performance characteristics.<b>Results</b>: Detection capabilities for the FIT method were 0.5 µg/g (limit of blank), 1.3 µg/g (limit of detection) and 3.0 µg/g (limit of quantitation). Of 33 non-homogenized specimens, 31 (93.9%) analysed in triplicate were consistently categorized relative to 10 µg/g, compared to all 33 (100%) homogenized specimens. Imprecision was higher (median 27.8%, (range 20.5% to 48.6%)) in non-homogenized specimens than in homogenized specimens (10.2%, (7.0 to 13.5%)). Considerable variation was observed in sequential clinical specimens from individual patients but no positive or negative trend in specimen degradation was observed over time (p = 0.26).<b>Discussion</b>: The FIT immunoassay evaluated is capable of detecting faecal Hb at concentrations well below the DG30 threshold of 10 µg/g and is suitable for application in this context. The greatest practical challenge to FIT performance is reproducible sampling, the pre-analytical step associated with most variability. Further research should focus on reducing sampling variability, particularly as post-COVID-19 guidance recommends greater FIT utilization.</p>\",\"PeriodicalId\":9236,\"journal\":{\"name\":\"British Journal of Biomedical Science\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2021-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1080/09674845.2021.1896204\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"British Journal of Biomedical Science\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/09674845.2021.1896204\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/3/19 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICAL LABORATORY TECHNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"British Journal of Biomedical Science","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09674845.2021.1896204","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/3/19 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}
引用次数: 5

摘要

简介:我们的目的是确定一种常用的粪便免疫化学试验(FIT)的分析能力,以检测在英国NICE DG30指南背景下参加初级保健的有症状患者的粪便血红蛋白(Hb)。材料和方法:从独立验证研究和HM-JACKarc FIT方法在常规初级保健实践中的临床试验中获得的数据进行分析,以得出性能特征。结果:FIT方法的检测能力分别为0.5µg/g(空白限)、1.3µg/g(检测限)和3.0µg/g(定量限)。在33个未匀浆的样本中,与所有33个(100%)匀浆的样本相比,31个(93.9%)的三次分析样本的分类相对于10µg/g一致。未匀浆标本的不精确性(中位数27.8%,范围20.5%至48.6%)高于匀浆标本(10.2%,范围7.0至13.5%)。在个体患者的连续临床标本中观察到相当大的变化,但随着时间的推移,没有观察到标本降解的阳性或阴性趋势(p = 0.26)。讨论:评估的FIT免疫分析法能够检测浓度远低于DG30阈值10µg/g的粪便Hb,适合在这种情况下应用。FIT性能的最大实际挑战是可重复采样,这是与大多数可变性相关的分析前步骤。进一步的研究应侧重于减少抽样变异性,特别是在covid -19后的指南建议提高FIT利用率的情况下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Faecal immunochemical testing (FIT): sources of result variation based on three years of routine testing of symptomatic patients in English primary care.

Introduction: We aimed to determine the analytical capabilities of a commonly used faecal immunochemical test (FIT) to detect faecal haemoglobin (Hb) in symptomatic people attending primary care in the context of the English NICE DG30 guidance.Materials and Methods: Data obtained from independent verification studies and clinical testing of the HM-JACKarc FIT method in routine primary care practice were analysed to derive performance characteristics.Results: Detection capabilities for the FIT method were 0.5 µg/g (limit of blank), 1.3 µg/g (limit of detection) and 3.0 µg/g (limit of quantitation). Of 33 non-homogenized specimens, 31 (93.9%) analysed in triplicate were consistently categorized relative to 10 µg/g, compared to all 33 (100%) homogenized specimens. Imprecision was higher (median 27.8%, (range 20.5% to 48.6%)) in non-homogenized specimens than in homogenized specimens (10.2%, (7.0 to 13.5%)). Considerable variation was observed in sequential clinical specimens from individual patients but no positive or negative trend in specimen degradation was observed over time (p = 0.26).Discussion: The FIT immunoassay evaluated is capable of detecting faecal Hb at concentrations well below the DG30 threshold of 10 µg/g and is suitable for application in this context. The greatest practical challenge to FIT performance is reproducible sampling, the pre-analytical step associated with most variability. Further research should focus on reducing sampling variability, particularly as post-COVID-19 guidance recommends greater FIT utilization.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
British Journal of Biomedical Science
British Journal of Biomedical Science 医学-医学实验技术
CiteScore
4.40
自引率
15.80%
发文量
29
审稿时长
>12 weeks
期刊介绍: The British Journal of Biomedical Science is committed to publishing high quality original research that represents a clear advance in the practice of biomedical science, and reviews that summarise recent advances in the field of biomedical science. The overall aim of the Journal is to provide a platform for the dissemination of new and innovative information on the diagnosis and management of disease that is valuable to the practicing laboratory scientist.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信